Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-α or donor lymphocytes following bone marrow transplantation

A. Toren, D. Novick, A. Ackerstein, R. Or, S. Slavin, A. Nagler*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Soluble interleukin-6 receptor (sIL-6R) has previously been shown to potentiate the activity of interleukin-6 (IL-6) which may display antitumor activity. Therefore, we evaluated sIL-6R levels in the sera of 15 patients who received cytokine-mediated immunotherapy with (IL-2/IFN-α), and 15 patients who received cell-mediated immunotherapy post-BMT, in an attempt to reduce the relapse rate, sIL-6R levels were evaluated pre-, during and post-cytokine or cell-mediated immunotherapy, using IL-6R-specific monoclonal antibodies (McAb) and double-sandwich ELISA. In normal controls, sIL-6R levels were found to be 20 ± 3 ng/ml. sIL-6R levels increased significantly during IL-2/IFN-α immunotherapy in comparison to pre- or post-immunoetherapy levels (74 ± 9 ng/ml vs 46 ± 6 ng/ml, and 50 ± 9 ng/ml, respectively) (n = 15) (P < 0.05), sIL-6R levels also significantly increased following donor lymphokine activated killer (LAK) cells, given in addition to IL-2, in comparison to base line levels (87 ± 3 ng/ml vs 60 ± 2 ng/ml) (It = 6) (P < 0.05). Increased levels of sIL-6R were observed in BMT patients treated with immunotherapy.

Original languageEnglish
Pages (from-to)721-724
Number of pages4
JournalBone Marrow Transplantation
Volume18
Issue number4
StatePublished - Oct 1996

Keywords

  • ABMT
  • Allogeneic BMT
  • Cell-mediated immunotherapy
  • Cytokine-mediated
  • Immunotherapy
  • Interleukin (IL-6)
  • Soluble interleukin-6 receptor (sIL-6R)

Fingerprint

Dive into the research topics of 'Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-α or donor lymphocytes following bone marrow transplantation'. Together they form a unique fingerprint.

Cite this